Congenital Heart Block – Executive Insights – Congenital Heart Block | Executive Insights | US/EU5 | 2022
Congenital heart block (CHB), also known as atrioventricular block, is a rare heart block disorder in which maternal antibodies attack the impulse-generating heart muscles of fetuses and newborns. Minimizing the deterioration of heart muscles and preventing disease progression are the key treatment goals in CHB. No therapies are approved for CHB, and patients are managed with off-label drugs such as dexamethasone and IVIG, or through plasmapheresis and pacemaker implantation. In addition, no commercial pharmacotherapies are in the pipeline for CHB. A major unmet need is for effective therapies and represents a commercial opportunity for drug developers in this market.
QUESTIONS ANSWERED
- What is the diagnosed incidence of CHB?
- What is the current market landscape including the diagnostic and management practices
- What are the current therapy and emerging therapy landscapes?
- What is the estimated cost of treatment in different geographies?
- What are the key unmet needs in the management of CHB?
- What are the key market drivers and limiters?
- What are the opinions of KOLs on different aspects of CHB?
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
GEOGRAPHY: United States, EU5
PRIMARY RESEARCH: 13 KOL interviews from November 2021 to January 2022
KEY DRUGS COVERED: Dexamethasone, intravenous immune globulin (IVIG)
